



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	GENES OVEREXPRESSED IN PROSTATE DISORDERS AS DIAGNOSTIC AND THERAPEUTIC TARGETS						
Application Number:	10/054498						
Confirmation Number:	4754						
First Named Applicant:	John WELSH						
Attorney Docket Number:	P0026US20						
Art Unit:	1642						
Examiner:	not yet assigned						
Search string:	(6329505 or 20020123081 or 20020110820 or 20020193296).pn.						
RECEIVED TECH CENTER 1600/2900 APR 21 2003							
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
Init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
✓	1	6329505	2001-12-11	Xu	B1	530	350

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

Init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
✓	1	20020123081	2002-09-05	Richardson	A1	435	7.23
✓	2	20020110820	2002-08-15	Ramaswamy	A1	435	6
✓	3	20020193296	2002-12-19	Xu	A1	514	12

Signature

Examiner Name	Date
<i>Xu</i>	21/04/05

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

NOV 15 2005
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

TECH CENTER 2400
RECEIVED
NOV 19 2002

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ³ (if known)			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Cite No. 1	Foreign Patent Document Country Code ⁴ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GW	AA	WO 01/34802 A2	May 17, 2001	Conda Corp.	T ⁶

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
GW	AB	BOOTCOV et al., Proc. Natl. Acad. Sci. USA, Vol. 94, No. 21, pp. 11514-11519 (1997); MiC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF- superfamily.			T ²
	AC	BRAWER, Semin. Surg. Oncol. 18: 3-8, 2000; Prostate-specific antigen.			
	AD	BRAWER et al., Am. J. Clin. Pathol. 92: 760-764, 1989; Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy.			
	AE	BUSSEMAKERS et al., Cancer Res., Vol. 59, pp. 5975-5979 (1999); DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.			
	AF	CATALONA et al., JAMA 270:948-954, 1993; Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.			
	AG	CHANG et al., Cancer Res., Vol. 57, pp. 4075-4081 (1997); Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.			

Examiner Signature	1/19/05	Date Considered	2/27/05
--------------------	---------	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002

PTO/SB/088(10-01)
Approved for use through 10/31/2002. OMB 0651-0203
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

Complete If Known	
Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

NOV 19 2002

RECEIVED

TECH CENTER 1600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SL	AH	CHOO et al., Prostate, Vol. 40, pp. 150-158 (1999); Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames.	
	AJ	DHANASEKARAN et al., Nature 412: 822-826 (2001); Delineation of prognostic biomarkers in prostate cancer.	
	AJ	EMMERT-BUCK et al., Am. J. Pathol., Vol. 158, pp. 1109-1115 (2000); Molecular Profiling of Clinical Tissue Specimens: Feasibility and Applications	
	AK	FERDINANDUSSE et al., J Lipid Res 2000 Nov;41(11):1890-6; Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.	
	AL	HOANG et al., Am. J. Pathol., Vol. 156, pp. 857-864 (2000); A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.	
	AM	HROMOS et al., Biochim. Biophys. Acta. Vol. 1354, No. 1, pp. 40-44 (1997); PLAB, a novel placental bone morphogenetic protein.	
	AN	HUANG et al., Genomics, Vol. 59, pp. 178-188 (1999); Prostate Cancer Expression Profiling by cDNA Sequencing Analysis.	
	AO	JIANG et al., Am. J. Surg. Pathol. 25: 1397-1404, 2001; P504S: a new molecular marker for the detection of prostate carcinoma.	
	AP	KANNAN et al., FEBS Lett., Vol. 470, No. 1, pp. 77-82 (2000); Profile of gene expression regulated by induced p53: connection to the TGF- β family.	
	AQ	KAZAMA, J. Biol. Chem., Vol. 270, pp. 66-72 (1995); Hepsin, a Putative Membrane-associated Serine Protease, Activates Human Factor VII and Initiates a Pathway of Blood Coagulation on the Cell Surface Leading to Thrombin Formation.	
	AR	KUHADJA, In Nutrition, Vol. 16, No. 3, pp. 202-208 (2000); Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.	
	AS	LALANI et al., Cancer Metastasis Rev., Vol. 16, pp. 29-66 (1997); Molecular and cellular biology of prostate cancer.	

Examiner Signature

1. *[Signature]*

Date Considered

2/22/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002

PTO/SB/08B (10-01)

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1615, TRADEMARK

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

Complete If Known

Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

NOV 19 2002

RECEIVED

TECH CENTER 1600 10/2000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gl	AT	Lt et al., Science, Vol. 275, pp. 1943-1947 (1997); PTEN, A Putative Protein Tyrosine Phosphatase Gene Mutated In Human Brain, Breast, and Prostate Cancer	
	AU	LUO et al., Cancer Res. 61: 4083-88, 2001; Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.	
	AV	MAGEE et al., Cancer Res. 61: 5692-96, 2001; Expression profiling reveals hepsin overexpression in prostate cancer.	
	AW	MARCELLI et al., Cancer Res., Vol. 60, pp. 944-949 (2000); Androgen receptor mutations in prostate cancer.	
	AX	MIKI et al., PNAS 98: 2199-2204, 2001; Defining developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays.	
	AY	NAM et al., J. Clin. Oncol. 18: 1036-1042, 2000; Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.	
	AZ	PILARSKY et al., Prostate, Vol. 38, pp. 85-91 (1998); Expression of the extracellular matrix signaling molecule Cys61 is downregulated in prostate cancer.	
	BA	PIZER et al., Prostate 2001 May 1;47(2):102-10; Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.	
	BB	SUN et al., Cancer Res., Vol. 57, pp. 18-23 (1997); Human prostatic carcinoma oncogene PT1-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples.	
	BC	SCHER et al., Urology 55: 323-327, 2000; Clinical states in prostate cancer: toward a dynamic model of disease progression.	
	BD	SAFFRAN et al., Cancer Metastasis Rev. 18: 437-449 (1999); Target antigens for prostate cancer immunotherapy.	

Examiner
Signature

1/22/05

Date
Considered

2/22/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002

PTO/SB/06B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

RECEIVED
NOV 19 2002
CPTC
CENTER-1000
2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM	BE	STAMEY et al., J. Urol. 166: 2171-77, 2001; Molecular genetic profiling of Gleeson grade 4/5 prostate cancers compared to benign prostatic hyperplasia.	
	BF	TANIMOTO et al., Cancer Res., Vol. 57, pp. 2684-2687 (1997); Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.	
	BG	TORRES-ROSADO et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 7181-7185 (1993); Hepsin, a Putative Cell-Surface Serine Protease, Is Required for Mammalian Cell Growth.	
	BH	TSUJI et al., J. Biol. Chem., Vol. 266, pp. 16948-16953 (1991); Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization.	
	BI	VOELLER et al., Cancer Res.; Vol. 58, pp. 2520-2523 (1998); Beta-catenin mutations in human prostate cancer.	
	BJ	VU et al., J. Biol. Chem., Vol. 272, pp. 31315-31320 (1997); Identification and Cloning of the Membrane-associated Serine Protease, Hepsin, from Mouse Preimplantation Embryos.	
	BK	WU et al., J. Clin. Invest., Vol. 101, pp. 321-326 (1998); Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.	
	BL	YANG et al., Cancer Res., Vol. 58, pp. 3732-3735 (1998); Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines.	

Examiner Signature	Date Considered
	2/22/05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.